1 |
Kochenderfer JN, Somerville RPT, Lu T et al (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35, 1803-1813
DOI
|
2 |
Colombo M, Raposo G and Thery C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30, 255-289
DOI
|
3 |
Raposo G, Nijman HW, Stoorvogel W et al (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183, 1161-1172
DOI
|
4 |
Hinshaw DC and Shevde LA (2019) the tumor microenvironment innately modulates cancer progression. Cancer Res 79, 4557-4566
DOI
|
5 |
Roma-Rodrigues C, Mendes R, Baptista PV and Fernandes AR (2019) Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20, 840
DOI
|
6 |
Baghban R, Roshangar L, Jahanban-Esfahlan R et al (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18, 59
DOI
|
7 |
Yu Y and Cui J (2018) Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol Lett 16, 4105-4113
|
8 |
Galluzzi L, Chan TA, Kroemer G, Wolchok JD and Lopez-Soto A (2018) The hallmarks of successful anticancer immunotherapy. Sci Transl Med 10, eaat7807
DOI
|
9 |
Chuah S and Chew V (2020) High-dimensional immuneprofiling in cancer: implications for immunotherapy. J Immunother Cancer 8, e000363
DOI
|
10 |
Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41 Suppl 5, S3-13
DOI
|
11 |
Rosenberg SA and Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68
DOI
|
12 |
Fu W, Lei C, Liu S et al (2019) CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun 10, 4355
DOI
|
13 |
Yang P, Cao X, Cai H et al (2021) The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol 360, 104262
DOI
|
14 |
Zhu L, Kalimuthu S, Gangadaran P et al (2017) Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7, 2732-2745
DOI
|
15 |
Neviani P, Wise PM, Murtadha M et al (2019) Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res 79, 1151-1164
DOI
|
16 |
Mathieu M, Martin-Jaular L, Lavieu G and Thery C (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21, 9-17
DOI
|
17 |
Kalluri R and LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367, eaau6977
DOI
|
18 |
Morse MA, Garst J, Osada T et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3, 9
DOI
|
19 |
Fais S (2013) NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology 2, e22337
DOI
|
20 |
Hong Y, Kim YK, Kim GB et al (2019) Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103(+) dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity. J Extracell Vesicles 8, 1670893
DOI
|
21 |
Slattery K and Gardiner CM (2019) NK cell metabolism and TGFbeta - implications for immunotherapy. Front Immunol 10, 2915
DOI
|
22 |
Khadka RH, Sakemura R, Kenderian SS and Johnson AJ (2019) Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy 11, 851-857
DOI
|
23 |
Murthy H, Iqbal M, Chavez JC and Kharfan-Dabaja MA (2019) Cytokine release syndrome: current perspectives. Immunotargets Ther 8, 43-52
DOI
|
24 |
Thommen DS and Schumacher TN (2018) T Cell dysfunction in cancer. Cancer Cell 33, 547-562
DOI
|
25 |
Hessvik NP and Llorente A (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci 75, 193-208
DOI
|
26 |
Escudier B, Dorval T, Chaput N et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 3, 10
DOI
|
27 |
Dai S, Wei D, Wu Z et al (2008) Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 16, 782-790
DOI
|
28 |
Riggan L, Shah S and O'Sullivan TE (2021) Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunology 10, e1238
|
29 |
Melaiu O, Lucarini V, Cifaldi L and Fruci D (2019) Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol 10, 3038
DOI
|
30 |
Thery C, Zitvogel L and Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2, 569-579
DOI
|
31 |
Zhang X, Liu L, Tang M, Li H, Guo X and Yang X (2020) The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm 46, 1150-1162
DOI
|
32 |
Cheng L, Wang Y and Huang L (2017) Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther 25, 1665-1675
DOI
|
33 |
Wang P, Wang H, Huang Q et al (2019) Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics 9, 1714-1727
DOI
|
34 |
Li J, Li N and Wang J (2020) M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect. Minerva Med [Online ahead of print]
|
35 |
Kim MS, Haney MJ, Zhao Y et al (2016) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655-664
DOI
|
36 |
Tian Y, Li S, Song J et al (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35, 2383-2390
DOI
|
37 |
Besse B, Charrier M, Lapierre V et al (2016) Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, e1071008
DOI
|
38 |
Jong AY, Wu CH, Li J et al (2017) Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles 6, 1294368
DOI
|
39 |
Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D and Vujanovic NL (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1, 1074-1083
DOI
|
40 |
Thery C, Ostrowski M and Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9, 581-593
DOI
|
41 |
Skotland T, Sandvig K and Llorente A (2017) Lipids in exosomes: current knowledge and the way forward. Prog Lipid Res 66, 30-41
DOI
|
42 |
Nam GH, Choi Y, Kim GB, Kim S, Kim SA and Kim IS (2020) Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater 32, e2002440
|
43 |
Jankovicova J, Secova P, Michalkova K and Antalikova J (2020) Tetraspanins, more than markers of extracellular vesicles in reproduction. Int J Mol Sci 21, 7568
DOI
|
44 |
Zhang Y, Bi J, Huang J, Tang Y, Du S and Li P (2020) Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine 15, 6917-6934
DOI
|
45 |
Yang D, Zhang W, Zhang H et al (2020) Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics 10, 3684-3707
DOI
|
46 |
Essand M and Loskog AS (2013) Genetically engineered T cells for the treatment of cancer. J Intern Med 273, 166-181
DOI
|
47 |
Tang H, Qiao J and Fu YX (2016) Immunotherapy and tumor microenvironment. Cancer Lett 370, 85-90
DOI
|
48 |
Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ and Darcy PK (2016) Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin Immunol 28, 64-72
DOI
|
49 |
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF and Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20, 7-24
DOI
|
50 |
Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377, 2545-2554
DOI
|
51 |
Rapoport AP, Stadtmauer EA, Aqui N et al (2009) Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 15, 4499-4507
DOI
|
52 |
Kundu S, Gurney M and O'Dwyer M (2021) Generating natural killer cells for adoptive transfer: expanding horizons. Cytotherapy 23, 559-566
DOI
|
53 |
Bollino D and Webb TJ (2017) Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res 187, 32-43
DOI
|
54 |
Tang X, Yang L, Li Z et al (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8, 1083-1089
|
55 |
Magalhaes I, Carvalho-Queiroz C, Hartana CA et al (2019) Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opin Biol Ther 19, 811-827
DOI
|
56 |
Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720
DOI
|
57 |
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851
DOI
|
58 |
Shimabukuro-Vornhagen A, Godel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6, 56
DOI
|
59 |
Rohaan MW, Wilgenhof S and Haanen J (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474, 449-461
DOI
|
60 |
Laskowski T and Rezvani K (2020) Adoptive cell therapy: Living drugs against cancer. J Exp Med 217, e20200377
DOI
|
61 |
Li L, Jay SM, Wang Y, Wu SW and Xiao Z (2017) IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+) T cells. Sci Rep 7, 13365
DOI
|
62 |
Nikfarjam S, Rezaie J, Kashanchi F and Jafari R (2020) Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res 39, 258
DOI
|
63 |
Ventimiglia LN and Alonso MA (2016) Biogenesis and function of T cell-derived exosomes. Front Cell Dev Biol 4, 84
DOI
|
64 |
Ventimiglia LN, Fernandez-Martin L, Martinez-Alonso E et al (2015) Cutting edge: regulation of exosome secretion by the integral MAL protein in T cells. J Immunol 195, 810-814
DOI
|
65 |
Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C et al (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2, 282
DOI
|
66 |
Lugini L, Cecchetti S, Huber V et al (2012) Immune surveillance properties of human NK cell-derived exosomes. J Immunol 189, 2833-2842
DOI
|
67 |
Dudley ME and Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3, 666-675
DOI
|
68 |
Kim GB, Nam GH, Hong Y et al (2020) Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity. Sci Adv 6, eaaz2083
DOI
|
69 |
Yang Y, Hong Y, Cho E, Kim GB and Kim IS (2018) Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery. J Extracell Vesicles 7, 1440131
DOI
|
70 |
Yang JC and Rosenberg SA (2016) Adoptive T-cell therapy for cancer. Adv Immunol 130, 279-294
DOI
|
71 |
Rosenberg SA, Packard BS, Aebersold PM et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319, 1676-1680
DOI
|
72 |
Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29, 917-924
DOI
|
73 |
Feins S, Kong W, Williams EF, Milone MC and Fraietta JA (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94, S3-S9
DOI
|
74 |
Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3, 16011
DOI
|
75 |
Zhang Y, Liu Y, Liu H and Tang WH (2019) Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci 9, 19
DOI
|
76 |
Koh E, Lee EJ, Nam GH et al (2017) Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis. Biomaterials 121, 121-129
DOI
|
77 |
Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA and Asgharzadeh S (2017) NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells. J Immunother 40, 265-276
DOI
|
78 |
Di Pace AL, Tumino N, Besi F et al (2020) Characterization of human NK cell-derived exosomes: Role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor. Cancers (Basel) 12, 661
DOI
|
79 |
Viaud S, Terme M, Flament C et al (2009) Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 4, e4942
DOI
|
80 |
Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15, 47-62
DOI
|
81 |
Shimasaki N, Jain A and Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19, 200-218
DOI
|
82 |
Liu S, Galat V, Galat Y, Lee YKA, Wainwright D and Wu J (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14, 7
DOI
|
83 |
Klingemann H, Boissel L and Toneguzzo F (2016) Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK Cells. Front Immunol 7, 91
DOI
|
84 |
Robbins PF, Kassim SH, Tran TL et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21, 1019-1027
DOI
|
85 |
Tran TH, Mattheolabakis G, Aldawsari H and Amiji M (2015) Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol 160, 46-58
DOI
|
86 |
Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129
DOI
|
87 |
Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546
|
88 |
Miliotou AN and Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19, 5-18
DOI
|
89 |
Comoli P, Chabannon C, Koehl U et al (2019) Development of adaptive immune effector therapies in solid tumors. Ann Oncol 30, 1740-1750
DOI
|
90 |
Jeppesen DK, Fenix AM, Franklin JL et al (2019) Reassessment of exosome composition. Cell 177, 428-445 e418
DOI
|
91 |
Alexander M, Culos K, Roddy J et al (2021) Chimeric antigen receptor T-cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration.Transplant Cell Ther 27, 558-570
DOI
|
92 |
Houot R, Schultz LM, Marabelle A and Kohrt H (2015) T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 3, 1115-1122
DOI
|
93 |
Pitt JM, Andre F, Amigorena S et al (2016) Dendritic cell-derived exosomes for cancer therapy. J Clin Invest 126, 1224-1232
DOI
|
94 |
Ott PA, Dotti G, Yee C and Goff SL (2019) An update on adoptive T-cell therapy and neoantigen vaccines. Am Soc Clin Oncol Educ Book 39, e70-e78
|
95 |
Parkhurst MR, Yang JC, Langan RC et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19, 620-626
DOI
|
96 |
Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507-1517
DOI
|
97 |
Hu W, Wang G, Huang D, Sui M and Xu Y (2019) cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 10, 1205
DOI
|
98 |
Bobrie A, Colombo M, Raposo G and Thery C (2011) Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659-1668
DOI
|
99 |
Li Q, Wang H, Peng H, Huyan T and Cacalano NA (2019) Exosomes: versatile nano mediators of immune regulation. Cancers (Basel) 11, 1557
DOI
|
100 |
Wahlgren J, Karlson Tde L, Glader P, Telemo E and Valadi H (2012) Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One 7, e49723
DOI
|
101 |
Hong Y, Nam GH, Koh E et al (2018) Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy. Adv Funct Mater 28, 1703074
DOI
|
102 |
Busatto S, Vilanilam G, Ticer T et al (2018) Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells 7, 273
DOI
|
103 |
Chen YS, Lin EY, Chiou TW and Harn HJ (2020) Exosomes in clinical trial and their production in compliance with good manufacturing practice. Ci Ji Yi Xue Za Zhi 32, 113-120
|
104 |
Whitford W and Guterstam P (2019) Exosome manufacturing status. Future Med Chem 11, 1225-1236
DOI
|